These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 17647267)

  • 1. Valproic acid for the treatment of myeloid malignancies.
    Kuendgen A; Gattermann N
    Cancer; 2007 Sep; 110(5):943-54. PubMed ID: 17647267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia.
    Kuendgen A; Knipp S; Fox F; Strupp C; Hildebrandt B; Steidl C; Germing U; Haas R; Gattermann N
    Ann Hematol; 2005 Dec; 84 Suppl 1():61-6. PubMed ID: 16270213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia.
    Kuendgen A; Schmid M; Schlenk R; Knipp S; Hildebrandt B; Steidl C; Germing U; Haas R; Dohner H; Gattermann N
    Cancer; 2006 Jan; 106(1):112-9. PubMed ID: 16323176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid.
    Pilatrino C; Cilloni D; Messa E; Morotti A; Giugliano E; Pautasso M; Familiari U; Cappia S; Pelicci PG; Lo Coco F; Saglio G; Guerrasio A
    Cancer; 2005 Jul; 104(1):101-9. PubMed ID: 15895376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia.
    Bug G; Ritter M; Wassmann B; Schoch C; Heinzel T; Schwarz K; Romanski A; Kramer OH; Kampfmann M; Hoelzer D; Neubauer A; Ruthardt M; Ottmann OG
    Cancer; 2005 Dec; 104(12):2717-25. PubMed ID: 16294345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia.
    Cimino G; Lo-Coco F; Fenu S; Travaglini L; Finolezzi E; Mancini M; Nanni M; Careddu A; Fazi F; Padula F; Fiorini R; Spiriti MA; Petti MC; Venditti A; Amadori S; Mandelli F; Pelicci PG; Nervi C
    Cancer Res; 2006 Sep; 66(17):8903-11. PubMed ID: 16951208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells.
    Trus MR; Yang L; Suarez Saiz F; Bordeleau L; Jurisica I; Minden MD
    Leukemia; 2005 Jul; 19(7):1161-8. PubMed ID: 15902297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
    Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
    Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulation of c-Myc is critical for valproic acid-induced growth arrest and myeloid differentiation of acute myeloid leukemia.
    Cheng YC; Lin H; Huang MJ; Chow JM; Lin S; Liu HE
    Leuk Res; 2007 Oct; 31(10):1403-11. PubMed ID: 17445886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response.
    Lagneaux L; Gillet N; Stamatopoulos B; Delforge A; Dejeneffe M; Massy M; Meuleman N; Kentos A; Martiat P; Willems L; Bron D
    Exp Hematol; 2007 Oct; 35(10):1527-37. PubMed ID: 17697742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor.
    Neri P; Tagliaferri P; Di Martino MT; Calimeri T; Amodio N; Bulotta A; Ventura M; Eramo PO; Viscomi C; Arbitrio M; Rossi M; Caraglia M; Munshi NC; Anderson KC; Tassone P
    Br J Haematol; 2008 Nov; 143(4):520-31. PubMed ID: 18986388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro.
    Kircher B; Schumacher P; Petzer A; Hoflehner E; Haun M; Wolf AM; Nachbaur D; Gastl G
    Eur J Haematol; 2009 Jul; 83(1):48-56. PubMed ID: 19226363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies.
    Blaheta RA; Michaelis M; Driever PH; Cinatl J
    Med Res Rev; 2005 Jul; 25(4):383-97. PubMed ID: 15637697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response of retinoic acid-resistant KG1 cells to combination of retinoic acid with diverse histone deacetylase inhibitors.
    Savickiene J; Treigyte G; Magnusson KE; Navakauskiene R
    Ann N Y Acad Sci; 2009 Aug; 1171():321-33. PubMed ID: 19723072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia.
    Raffoux E; Chaibi P; Dombret H; Degos L
    Haematologica; 2005 Jul; 90(7):986-8. PubMed ID: 15996941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibitor valproic acid inhibits proliferation and induces apoptosis in KM3 cells via downregulating VEGF receptor.
    Dong XF; Song Q; Li LZ; Zhao CL; Wang LQ
    Neuro Endocrinol Lett; 2007 Dec; 28(6):775-80. PubMed ID: 18063935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy on anaplastic thyroid carcinoma of valproic acid alone or in combination with doxorubicin, a synthetic chenodeoxycholic acid derivative, or lactacystin.
    Kim TH; Yoo YH; Kang DY; Suh H; Park MK; Park KJ; Kim SH
    Int J Oncol; 2009 May; 34(5):1353-62. PubMed ID: 19360347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel valproic acid derivatives with potent differentiation-inducing activity in myeloid leukemia cells.
    Deubzer H; Busche B; Rönndahl G; Eikel D; Michaelis M; Cinatl J; Schulze S; Nau H; Witt O
    Leuk Res; 2006 Sep; 30(9):1167-75. PubMed ID: 16510182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial.
    Daud AI; Dawson J; DeConti RC; Bicaku E; Marchion D; Bastien S; Hausheer FA; Lush R; Neuger A; Sullivan DM; Munster PN
    Clin Cancer Res; 2009 Apr; 15(7):2479-87. PubMed ID: 19318485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of histone deacetylase inhibitors on the cell nucleus and nucleolus of leukemic myeloblasts in vitro - a cytochemical study.
    Smetana K; Zápotocký M; Starková J; Trka J
    Acta Histochem; 2007; 109(5):413-9. PubMed ID: 17559910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.